Amol M. Takalkar, MD, MS, MBA, FACNM

Role

Nuclear Medicine
Specialty

Bile Duct (Biliary) Cancer Breast Cancer Colorectal Cancer Esophageal Cancer Liver Cancer Pancreatic Cancer
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2005

Background

Amol M. Takalkar, MD, MS, MBA, FACNM, is a board certified nuclear medicine and molecular imaging specialist with expertise in PET/CT probes and in targeted internal radiation therapies with therapeutic radionuclides.

Titles & Roles

Professor, Department of Radiology and Imaging Sciences

Emory University School of Medicine

Education & Training

Education

Residency, Nuclear Medicine, 2005
Hospital of Univ of Pennsylvania
Internship, General Surgery, 2003
Lenox Hill Hospital
Medical Education, MD, 1999
B. J. Medical College

Board Certifications

Nuclear Medicine
American Board of Nuclear Medicine, 2005

Professional Memberships

Society of Nuclear Medicine & Molecular Imaging
American College of Nuclear Medicine
Radiological Society of North America
American College of Radiology
Indo-American Society of Nuclear Medicine

Research

Dr. Takalkar's research interests include molecular imaging and therapy using fluorodeoxyglucose and other PET probes for oncology, cardiovascular, neurological and inflammatory pathologies.

View Current Clinical Trials


Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. Phase I/II Conditions Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer Location Winship Cancer Institute
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase Early Phase I Conditions Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 Location Emory University Hospital Midtown
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer Phase IV Conditions Prostate Cancer Location Winship Cancer Institute
Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Phase I/II Conditions GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET Location Emory University Hospital Midtown

Publications

Title/Journal	Authors	Publication Date
Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101. Future oncology (London, England)	US Grewal, OB Gbolahan, AM Takalkar, DM Halperin	05/01/2025
Longitudinal Evaluation of FDG Uptake in a Synovial Herniation Pit in 8 Years: Implications for Potential False-Positive PET Findings. Clinical nuclear medicine	C Wu, AM Takalkar	03/01/2025
Molecular Imaging of Breast Cancer Molecular Imaging and Therapy	LT Hall, VS Krishnaraju, H Singh, LT Hall, AM Takalkar, BR Mittal	11/08/2023
Molecular Imaging of Head and Neck Cancers Molecular Imaging and Therapy	LT Hall, S Jain, AM Takalkar, LT Hall	11/08/2023
Molecular Imaging of Hepatobiliary Cancers Molecular Imaging and Therapy	LT Hall, K Subramanian, P Aggarwal, LT Hall, H Singh, AM Takalkar, BR Mittal	11/08/2023
Molecular Imaging of Lung and Pleural Tumors Molecular Imaging and Therapy	LT Hall, T Sivathapandi, J Amalchandran, A Takalkar, LT Hall	11/08/2023
Molecular Imaging of Mediastinal Tumors Molecular Imaging and Therapy	LT Hall, J Amalachandran, A Takalkar, T Sivathapandi, LT Hall	11/08/2023
Molecular Imaging of Pediatric Lymphoma, Sarcomas, and Other Solid Tumors Molecular Imaging and Therapy	LT Hall, Y Mathur, K Shankar, H Veerwal, S Kumar, R Kumar, AM Takalkar, LT Hall	11/08/2023
Mickey Mouse Sign on Bone Scan: This Mouseketeer Rebels Against Paget Disease. Clinical nuclear medicine	FM Khan, B Chen, AM Takalkar	04/01/2022

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.